Provide a proper "Assessment of Eye " diagnosed with sclerosis. Give Biographic data, chief complaints, present illness, past illness, physical Examination , lab investigations, medicine, special investigations of the patient.
Reading File
Finding Sources
Finding Sources
Searching the Web
eye sclerosis clinical assessment biographic data nursing care plan physical examination investigations
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive clinical information to construct a thorough patient assessment. Let me compile the full structured assessment.
Patient Assessment: Eye Scleritis (Scleral Sclerosis / Scleritis)
Scleritis is the inflammatory condition of the sclera (the white "coat" of the eye) involving oedema and cellular infiltration of the entire scleral thickness. When clinicians refer to "sclerosis of the eye," they typically mean scleritis or scleromalacia - a progressive sclerosing/fibrotic process of the sclera, often linked to autoimmune connective tissue diseases.
I. BIOGRAPHIC DATA
| Item | Details |
|---|---|
| Patient Name | Mrs. Anita Sharma (Hypothetical Case) |
| Age | 52 years |
| Sex | Female |
| Occupation | Schoolteacher |
| Marital Status | Married |
| Religion | Hindu |
| Address | Urban residential area |
| Education | Graduate |
| Date of Admission | July 23, 2026 |
| Ward | Ophthalmology OPD / Eye Ward |
| Attending Consultant | Ophthalmologist |
| Referred by | General Physician |
| Diagnosis | Diffuse Anterior Scleritis with Scleral Sclerosis (associated with Rheumatoid Arthritis) |
| Informant | Patient herself (reliable historian) |
II. CHIEF COMPLAINTS
The patient presents with the following complaints (in order of severity and onset):
- Severe, deep, boring pain in the right eye - 3 weeks duration
- Redness of the right eye - 3 weeks duration
- Waking from sleep due to eye pain at night - 2 weeks duration
- Blurring of vision in the right eye - 1 week duration
- Photophobia (light sensitivity) - 1 week duration
- Excessive tearing (epiphora) - 1 week duration
- Pain radiating to the forehead, brow, and temple - 1 week duration
III. HISTORY OF PRESENT ILLNESS
The patient is a 52-year-old female who was apparently well 3 weeks ago, when she began noticing a gradually increasing redness of the right eye associated with a deep, severe, boring-type pain. The pain was initially mild but progressively worsened over the next few days, eventually waking her from sleep in the early morning hours - a hallmark feature of scleritis. The pain is aggravated by eye movement and direct touch over the eye.
One week ago, she developed blurring of vision in the right eye, photophobia, and excessive tearing. The pain radiates to the right side of the forehead, brow, jaw, and sinuses. She denies any discharge from the eye. She has no history of trauma, recent eye surgery, or foreign body entry.
She was previously diagnosed with Rheumatoid Arthritis (RA) 8 years ago and is on irregular follow-up. She reports that her joints (especially the small joints of both hands) have been more painful over the past month. There is no history of similar eye episodes in the past.
- Onset: Insidious
- Duration: 3 weeks
- Progression: Gradually worsening
- Aggravating factors: Eye movement, exposure to bright light, touch
- Relieving factors: Darkness, rest (partial)
- Associated features: Pain radiates to the face and temple; disrupts sleep
- Treatment sought so far: Tried OTC lubricating eye drops and paracetamol - no significant relief
IV. PAST ILLNESS HISTORY
| Category | Details |
|---|---|
| Systemic Disease | Rheumatoid Arthritis - diagnosed 8 years ago; currently on Methotrexate 10 mg/week (irregular compliance) |
| Previous Eye Disease | No previous scleritis, uveitis, or glaucoma |
| Surgical History | Appendectomy 15 years ago |
| Hospitalization | 1 hospitalization for RA joint flare (3 years ago) |
| Allergies | No known drug allergies |
| Medications (ongoing) | Methotrexate 10 mg weekly; Tablet Folic Acid 5 mg weekly; occasional Ibuprofen for joint pain |
| Immunization | BCG scar present; routine vaccinations as child |
| Family History | Mother had Rheumatoid Arthritis; no family history of eye disease, tuberculosis, or malignancy |
| Menstrual/Obstetric | Menopause at age 48; G3P3 - 3 normal vaginal deliveries |
| Social History | Non-smoker, non-alcoholic, no illicit drug use; lives with husband and two adult children |
V. PHYSICAL EXAMINATION
A. General Examination
| Parameter | Finding |
|---|---|
| Conscious level | Conscious, alert, oriented to time, place, and person |
| Built | Average |
| Nourishment | Adequately nourished |
| Pallor | Mild pallor present (chronic disease anemia suspected) |
| Icterus | Absent |
| Cyanosis | Absent |
| Clubbing | Absent |
| Lymphadenopathy | No regional lymphadenopathy |
| Edema | No pedal edema |
| Pulse | 88/min, regular, normal volume |
| Blood Pressure | 126/80 mmHg |
| Temperature | 37.2°C (99°F) - low-grade |
| Respiratory Rate | 18/min |
| Height / Weight | 158 cm / 62 kg; BMI 24.8 |
| Pain Score (VAS) | 7/10 (right eye) |
B. Systemic Examination
- Musculoskeletal: Bilateral symmetrical swelling, warmth, and tenderness of metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints; early morning stiffness reported; no deformity yet; consistent with active Rheumatoid Arthritis
- Cardiovascular: S1 and S2 heart sounds heard; no murmurs
- Respiratory: Air entry bilaterally equal; no added sounds
- Abdomen: Soft, non-tender; no organomegaly; appendectomy scar present
- Neurological: No focal neurological deficit; cranial nerves intact
- Skin: No rash, no subcutaneous nodules over extensor surfaces
C. Ocular Examination - Right Eye (Affected Eye)
| Feature | Findings |
|---|---|
| Visual Acuity (Snellen) | Right: 6/18 (reduced); Left: 6/6 (normal) |
| Extraocular Movements | Right eye - pain on all directions of gaze |
| Eyelids | Mild right upper lid edema |
| Conjunctiva | Diffuse hyperemia; chemosis present |
| Sclera | Deep, violaceous (bluish-red) discoloration of the right sclera; non-mobile large dilated deep scleral vessels; vascular congestion; NO blanching with 2.5% / 10% phenylephrine drops - confirming scleral (not episcleral) involvement |
| Cornea | Early peripheral keratitis at the limbus (inferior quadrant) |
| Anterior Chamber | Mild flare; 1+ cells (early uveitis) |
| Pupil | 4mm, reactive to light; relative afferent pupillary defect (RAPD) absent |
| Lens | Clear |
| Intraocular Pressure (IOP) | Right: 24 mmHg (mildly elevated); Left: 15 mmHg (normal) |
| Slit Lamp Examination | Scleral edema with large, immovable, deep injected vessels; red-free (green) filter shows no avascular scleral areas |
| Fundus (dilated) | Optic disc - normal margins; cup-disc ratio 0.3; no subretinal fluid, no choroidal folds, no retinal detachment |
| B-Scan Ultrasonography | Slight scleral thickening noted; No "T-sign" (T-sign would indicate posterior scleritis) |
Source: The Wills Eye Manual - Office and Emergency Room Diagnosis and Treatment of Eye Disease; Kanski's Clinical Ophthalmology, 10th ed.
VI. LABORATORY INVESTIGATIONS
The following investigations are ordered to characterize the scleritis and identify the underlying systemic cause:
Routine Blood Tests
| Test | Result | Reference Range | Interpretation |
|---|---|---|---|
| Hemoglobin | 10.8 g/dL | 12-16 g/dL (F) | Low - Anemia of chronic disease |
| Total WBC | 9,200 cells/µL | 4,000-11,000 | Normal |
| Platelet Count | 3.8 lakhs/µL | 1.5-4.5 lakhs | Normal |
| ESR (Westergren) | 68 mm/hr | 0-20 mm/hr (F) | Elevated - Active inflammation |
| CRP | 28 mg/L | <5 mg/L | Elevated - Active inflammation |
| Blood Glucose (Fasting) | 98 mg/dL | 70-110 mg/dL | Normal |
| Serum Creatinine | 0.9 mg/dL | 0.5-1.1 mg/dL | Normal |
| Uric Acid | 5.1 mg/dL | 2.4-6.0 mg/dL | Normal |
| Liver Function Tests | Within normal limits | - | Normal |
| Urinalysis | No protein, no RBCs, no casts | - | Normal |
Immunological / Autoimmune Tests
| Test | Result | Significance |
|---|---|---|
| Rheumatoid Factor (RF) | Positive (1:320) | Strongly positive - supports RA-associated scleritis |
| Anti-CCP antibody | Positive (>200 U/mL) | Highly specific for RA |
| ANA (Antinuclear Antibody) | Weakly positive (1:80, speckled) | May indicate overlap |
| Anti-dsDNA | Negative | SLE less likely |
| ANCA (c-ANCA / p-ANCA) | Negative | GPA/vasculitis less likely |
| Complement (C3, C4, CH50) | Normal | |
| ACE (Angiotensin Converting Enzyme) | Normal | Sarcoidosis less likely |
Infectious Disease Screen
| Test | Result |
|---|---|
| RPR / VDRL | Negative (Syphilis ruled out) |
| FTA-ABS (Treponemal test) | Negative |
| Mantoux (PPD) / IGRA | Negative (TB less likely) |
| Lyme Antibody (IgG, IgM) | Negative |
| Chest X-Ray (PA view) | Normal lung fields; no hilar lymphadenopathy |
| HLA B27 | Negative |
Source: The Wills Eye Manual, 9781975160753; EyeWiki - Scleritis Laboratory Workup
VII. MEDICATIONS PRESCRIBED
1. Step 1 - NSAIDs (First-line for diffuse/nodular scleritis)
| Drug | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Flurbiprofen | 100 mg | Oral | Three times daily (TID) | 4-6 weeks then reassess |
| OR Naproxen | 250-500 mg | Oral | Twice daily (BID) | Alternative NSAID |
| OR Indomethacin | 25-50 mg | Oral | Three times daily | Alternative NSAID |
Several different NSAIDs may be tried before therapy is considered a failure.
2. Gastroprotection (with NSAIDs)
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Omeprazole | 20 mg | Oral | Once daily (OD) |
3. Corticosteroids (if NSAIDs fail or disease is severe)
| Drug | Dose | Route | Frequency |
|---|---|---|---|
| Prednisolone | 60 mg | Oral | Once daily, then taper over 2-6 weeks |
| Calcium + Vitamin D | 600 mg + 400 IU | Oral | Once daily (to prevent osteoporosis during steroid use) |
4. Topical Eye Treatment
| Drug | Dose | Route | Frequency | Purpose |
|---|---|---|---|---|
| Difluprednate 0.05% eye drops | 1 drop | Topical (right eye) | 4 times daily | Mild local anti-inflammatory effect |
| Lubricating eye drops (Carboxymethylcellulose) | 1-2 drops | Topical | As needed (every 2-4 hrs) | Comfort / dryness |
| Timolol 0.5% eye drops | 1 drop | Topical | Twice daily | Control elevated IOP (24 mmHg right eye) |
5. Disease-Modifying Antirheumatic Drug (DMARD) - for underlying RA
| Drug | Dose | Route | Frequency | Note |
|---|---|---|---|---|
| Methotrexate | 15 mg (dose escalation) | Oral | Once weekly | Coordinate with rheumatologist; folic acid supplementation essential |
| Folic acid | 5 mg | Oral | Once weekly (day after MTX) | Reduces MTX toxicity |
6. Immunosuppressives (for refractory or necrotizing disease - if needed)
| Drug | Examples | Note |
|---|---|---|
| Cyclophosphamide / Azathioprine / Mycophenolate | Per rheumatology guidance | Coordinate with internist/rheumatologist |
| Biologic agents (anti-TNF) | Adalimumab / Infliximab | For refractory RA-associated scleritis |
Source: The Wills Eye Manual, pp. 341-346; Goldman-Cecil Medicine International Edition
VIII. SPECIAL INVESTIGATIONS
Ophthalmic Imaging & Specialized Tests
| Investigation | Purpose | Expected Finding in Scleritis |
|---|---|---|
| Slit Lamp Biomicroscopy | Assess depth and extent of scleral inflammation; rule out corneal/AC involvement | Deep, immovable scleral vessel engorgement; violaceous discoloration; scleral edema; early peripheral keratitis |
| Slit Lamp with Red-Free (Green) Filter | Detect avascular scleral zones suggesting necrotizing change | No avascular areas in this patient (non-necrotizing) |
| Phenylephrine (10%) Blanching Test | Differentiate scleritis from episcleritis | No blanching = scleritis confirmed (episcleral vessels blanch, scleral do not) |
| Tonometry (IOP measurement) | Monitor for secondary glaucoma (most common cause of visual loss in scleritis) | Right eye IOP = 24 mmHg (mildly elevated) |
| B-Scan Ocular Ultrasonography | Detect posterior scleritis; assess scleral thickening; "T-sign" | Mild scleral thickening; no T-sign (posterior scleritis absent) |
| Fluorescein Angiography (FA) | Used if posterior scleritis suspected; shows pinpoint leakage, choroidal folds | Not indicated here (no posterior signs) |
| Optical Coherence Tomography (OCT) | Assess macular edema, retinal involvement | Normal in this patient |
| Gonioscopy | Evaluate anterior chamber angle for secondary angle-closure glaucoma | Normal open angle |
| Fundus Photography | Document optic disc and posterior segment | Normal; no subretinal fluid or disc swelling |
Systemic Imaging
| Investigation | Purpose |
|---|---|
| Chest X-Ray (PA View) | Rule out sarcoidosis, TB, granulomatosis with polyangiitis (GPA) |
| X-Ray of Sacroiliac Joints | Rule out ankylosing spondylitis (HLA B27 negative here) |
| MRI Orbit | Indicated if orbital pseudotumor or posterior extension suspected; also useful for posterior scleritis characterization |
| Radiograph of Hands/Wrists | Assess RA severity (erosions, joint space narrowing) |
IX. NURSING DIAGNOSIS & CARE PLAN (Summary)
| Priority | Nursing Diagnosis | Goal | Interventions |
|---|---|---|---|
| 1 | Acute pain (right eye) related to scleral inflammation | Patient reports pain VAS ≤3 within 48 hrs | Administer NSAIDs/steroids as prescribed; apply cool compresses; dim lights; educate patient to avoid rubbing eye |
| 2 | Disturbed sensory perception (visual) related to corneal/AC involvement | Stabilize and improve visual acuity | Monitor VA daily; administer prescribed eye drops; refer to ophthalmologist if VA worsens |
| 3 | Sleep disturbance related to nocturnal eye pain | Patient sleeps uninterrupted 6+ hours | Ensure analgesics are given at bedtime; dim ward lighting; maintain quiet environment |
| 4 | Anxiety related to fear of vision loss | Patient verbalizes reduced anxiety | Provide education about disease, prognosis (good if treated), treatment expectations |
| 5 | Non-compliance with RA medications (Methotrexate) | Patient maintains regular medication schedule | Medication education; explain link between RA control and scleritis prevention; refer to rheumatology |
| 6 | Risk for visual impairment related to elevated IOP | IOP maintained within normal range | Administer Timolol eye drops; monitor IOP at each visit |
X. FOLLOW-UP & PROGNOSIS
- Review: Every 2 weeks for the first 2 months; then monthly
- Monitor: Visual acuity, IOP, slit lamp findings, inflammatory markers (ESR, CRP), renal/liver function (Methotrexate toxicity)
- Rheumatology referral: Mandatory to optimize RA therapy and coordinate systemic immunosuppression
- Prognosis: For diffuse anterior non-necrotizing scleritis, the long-term visual prognosis is good when treated appropriately. Average disease duration is approximately 6 years, with decreasing recurrences after the first 18 months. The greatest risk to vision is secondary glaucoma from elevated IOP.
"Glaucoma is the commonest cause of visual loss in anterior scleritis, so control of the IOP is critically important."
- Kanski's Clinical Ophthalmology, 10th Edition
References:
- Kanski's Clinical Ophthalmology: A Systematic Approach, 10th Edition (ISBN 9780443110993), pp. 308-311
- The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease (ISBN 9781975160753), pp. 341-346
- Goldman-Cecil Medicine International Edition, 2-Volume Set (ISBN 9780323930345)
- EyeWiki - Scleritis - Laboratory testing and management
- Medscape - Scleritis Clinical Presentation - Physical examination
Provide the assessment with Diabetic Retinopathy
Finding Sources
Searching the Web
diabetic retinopathy clinical assessment physical examination lab investigations treatment nursing care plan
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have thorough clinical data from authoritative textbooks. Let me compile the complete assessment.
Patient Assessment: Diabetic Retinopathy
I. BIOGRAPHIC DATA
| Item | Details |
|---|---|
| Patient Name | Mr. Ramesh Patel (Hypothetical Case) |
| Age | 58 years |
| Sex | Male |
| Occupation | Retired Bank Officer |
| Marital Status | Married |
| Religion | Hindu |
| Address | Semi-urban residential area |
| Education | Graduate |
| Date of Admission | July 23, 2026 |
| Ward | Ophthalmology OPD / Retina Clinic |
| Attending Consultant | Ophthalmologist / Retina Specialist |
| Referred by | Diabetologist / General Physician |
| Diagnosis | Moderate Non-Proliferative Diabetic Retinopathy (NPDR) with Clinically Significant Diabetic Macular Edema (DME), Right Eye > Left Eye |
| Informant | Patient himself (reliable historian) |
II. CHIEF COMPLAINTS
- Blurring of vision in both eyes - 6 months (gradual, progressive; worse in right eye)
- Difficulty reading small print - 4 months
- Floaters (black spots/cobwebs) in front of right eye - 2 months
- Distortion of straight lines (metamorphopsia) - 6 weeks
- Decreased color perception - 1 month
- No pain in either eye
III. HISTORY OF PRESENT ILLNESS
Mr. Ramesh Patel is a 58-year-old male with a known 14-year history of Type 2 Diabetes Mellitus, who presents with a gradual, progressive, painless decline in vision in both eyes over the past 6 months, more pronounced in the right eye.
He first noticed difficulty reading fine print 4 months ago, which he attributed to "age-related changes." Two months ago, he began seeing floaters (black spots and cobwebs) in his right eye. Over the past 6 weeks, he noticed distortion when looking at straight lines (door frames appearing wavy), which prompted him to seek medical attention. He also reports a decrease in color brightness in the right eye.
He has been a known diabetic for 14 years, managed on oral hypoglycemic agents. He admits to poor dietary compliance and irregular blood glucose monitoring. His last HbA1c (6 months ago) was 9.4%. He also has hypertension for the past 8 years, controlled on amlodipine 5 mg once daily. He has not had any eye examination in over 3 years.
There is no history of eye trauma, eye surgery, or use of steroids. No history of sudden vision loss, curtain-like defect, or flashes of light.
- Onset: Insidious and gradual
- Duration: 6 months (blurred vision); 2 months (floaters)
- Progression: Slowly progressive
- Aggravating factors: Bright light, reading
- Relieving factors: None significant
- Associated systemic symptoms: Generalized fatigue, polyuria, polydipsia (suggesting poor glycemic control)
IV. PAST ILLNESS HISTORY
| Category | Details |
|---|---|
| Systemic Disease 1 | Type 2 Diabetes Mellitus - 14 years; managed with Metformin 1000 mg BD + Glimepiride 2 mg OD; irregular HbA1c monitoring; last HbA1c = 9.4% |
| Systemic Disease 2 | Hypertension - 8 years; Amlodipine 5 mg OD; BP generally >140/90 mmHg at home |
| Systemic Disease 3 | Dyslipidemia - diagnosed 4 years ago; on Atorvastatin 20 mg OD |
| Previous Eye Disease | No previous eye surgery; no known glaucoma or cataract treatment; last eye exam 3 years ago (no retinopathy documented at that time) |
| Renal History | Microalbuminuria detected 2 years ago (early diabetic nephropathy); no dialysis |
| Surgical History | Inguinal hernia repair 20 years ago |
| Allergies | No known drug allergies |
| Family History | Father - Type 2 Diabetes + hypertension; Mother - died of stroke; one sibling with diabetes |
| Social History | Retired; sedentary lifestyle; non-smoker; occasional alcohol; high-carbohydrate diet; BMI 29 (overweight) |
| Immunization | Influenza vaccine annually; hepatitis B vaccinated |
V. PHYSICAL EXAMINATION
A. General Examination
| Parameter | Finding |
|---|---|
| Conscious level | Conscious, alert, well-oriented |
| Built | Stocky, overweight |
| Nourishment | Well-nourished |
| Pallor | Absent |
| Icterus | Absent |
| Cyanosis | Absent |
| Clubbing | Absent |
| Lymphadenopathy | Absent |
| Edema | Bilateral mild pedal edema (1+) |
| Pulse | 84/min, regular |
| Blood Pressure | 148/92 mmHg (elevated - not well controlled) |
| Temperature | 37.0°C (afebrile) |
| Respiratory Rate | 16/min |
| Height / Weight | 168 cm / 82 kg; BMI = 29.0 (overweight) |
| Random Blood Sugar (bedside glucometer) | 248 mg/dL (poorly controlled) |
B. Systemic Examination
- Cardiovascular: S1, S2 audible; no murmurs; mild cardiomegaly clinically; peripheral pulses palpable bilaterally
- Respiratory: Normal vesicular breath sounds; no added sounds
- Abdomen: Soft, non-tender; no hepatosplenomegaly; appendectomy scar noted
- Neurological: Peripheral neuropathy findings - reduced vibration sense in both feet; diminished ankle jerks bilaterally; glove-and-stocking pattern hypoesthesia (consistent with diabetic peripheral neuropathy)
- Feet: No ulcers; dry skin; reduced sensation to monofilament test; nail thickening noted
- Skin: Acanthosis nigricans at the nape; no xanthomas
C. Ocular Examination
External Eye
| Feature | Right Eye | Left Eye |
|---|---|---|
| Visual Acuity (Snellen - Unaided) | 6/36 (moderately reduced) | 6/18 (mildly reduced) |
| Visual Acuity (BCVA with correction) | 6/24 | 6/12 |
| Color Vision (Ishihara) | Mildly impaired | Intact |
| Eyelids | Normal | Normal |
| Conjunctiva | No injection | No injection |
| Cornea | Clear | Clear |
| Anterior Chamber | Normal depth, no cells/flare | Normal |
| Iris | No neovascularization of iris (NVI) | No NVI |
| Pupil | 4 mm, reacts to light | 4 mm, reacts to light |
| Lens | Early posterior subcapsular opacity (early cataract) | Clear |
| IOP (Tonometry) | 18 mmHg | 16 mmHg |
| Gonioscopy | No neovascularization of angle (NVA) | Normal |
Fundus Examination (Dilated Ophthalmoscopy - Indirect + 90D Slit Lamp)
| Feature | Right Eye | Left Eye |
|---|---|---|
| Optic Disc | Normal margins, C:D ratio 0.3, no new vessels on disc (NVD) | Normal |
| Macula | Hard exudates within 500 µm of foveal center; retinal thickening at fovea (Clinically Significant Macular Edema - CSME) | Hard exudates present; no center-involving thickening |
| Microaneurysms | Numerous, scattered - temporal to fovea and throughout posterior pole | Few, temporal to fovea |
| Dot/Blot Hemorrhages | Multiple in all quadrants | Few, posterior pole |
| Hard Exudates | Ring/circinate pattern near fovea | Present, not threatening fovea |
| Cotton-Wool Spots | 2-3 (nerve fiber layer infarcts) | 1 cotton-wool spot |
| Venous Beading | Present in 1 quadrant | Absent |
| IRMA (Intraretinal microvascular anomalies) | Present | Absent |
| New Vessels (NVE/NVD) | Absent | Absent |
| Vitreous | Clear; no hemorrhage | Clear |
| Periphery | No tractional changes | Normal |
| Classification | Moderate NPDR + CSME (Right eye) | Mild NPDR (Left eye) |
Source: Kanski's Clinical Ophthalmology 10th Edition; The Wills Eye Manual
VI. LABORATORY INVESTIGATIONS
Routine Blood Tests
| Test | Result | Reference Range | Interpretation |
|---|---|---|---|
| Fasting Blood Sugar | 186 mg/dL | 70-110 mg/dL | High - Poor glycemic control |
| Post-Prandial Blood Sugar (2hr PP) | 312 mg/dL | <140 mg/dL | High |
| HbA1c | 9.8% | <7.0% (target in DM) | Poorly controlled diabetes |
| Fasting Lipid Profile | |||
| - Total Cholesterol | 228 mg/dL | <200 mg/dL | Borderline high |
| - LDL Cholesterol | 148 mg/dL | <100 mg/dL in DM | Elevated |
| - HDL Cholesterol | 38 mg/dL | >40 mg/dL | Low |
| - Triglycerides | 210 mg/dL | <150 mg/dL | Elevated |
| Hemoglobin | 11.2 g/dL | 13-17 g/dL (M) | Low - anemia (risk factor for DR progression) |
| Total WBC | 8,400 cells/µL | 4,000-11,000 | Normal |
| Platelet Count | 2.2 lakhs/µL | 1.5-4.5 lakhs | Normal |
| ESR | 32 mm/hr | 0-15 mm/hr (M) | Mildly elevated |
| Serum Creatinine | 1.6 mg/dL | 0.7-1.2 mg/dL | Elevated - early diabetic nephropathy |
| eGFR | 48 mL/min/1.73m² | >60 | Stage 3a CKD |
| Blood Urea Nitrogen | 26 mg/dL | 7-20 mg/dL | Mildly elevated |
| Serum Electrolytes | Na: 138, K: 4.1 | Normal | Normal |
| Liver Function Tests | Within normal limits | - | Normal |
Urine Tests
| Test | Result | Significance |
|---|---|---|
| Urine Routine | Sugar: 2+, Protein: 1+, No RBC/casts | Glycosuria; proteinuria (nephropathy) |
| Urine Albumin-Creatinine Ratio (ACR) | 185 mg/g creatinine | >30 = microalbuminuria; >300 = macroalbuminuria - elevated |
| 24-hr Urine Protein | 620 mg/day | >300 mg/day = overt nephropathy |
Cardiac Investigation
| Test | Result |
|---|---|
| ECG | Sinus rhythm; LVH pattern (Sokolov-Lyon criteria) |
| 2D Echocardiography | Concentric LVH; EF 55%; diastolic dysfunction Grade I |
| Chest X-Ray (PA) | Mild cardiomegaly |
VII. SPECIAL INVESTIGATIONS (Ophthalmic)
| Investigation | Purpose | Findings |
|---|---|---|
| Dilated Fundus Examination (90D / Indirect Ophthalmoscopy) | Primary assessment of retinopathy severity | Moderate NPDR with CSME right eye; Mild NPDR left eye |
| Slit Lamp Biomicroscopy (with fundus contact lens) | Stereoscopic view of macula and disc; detect macular edema and neovascularization | Retinal thickening at and within 500 µm of foveal center (Right eye); CSME confirmed |
| Optical Coherence Tomography (OCT - Macula) | Gold standard for quantifying DME; measures central retinal thickness | Right eye: Central macular thickness 420 µm (normal <250 µm); Subretinal/intraretinal fluid present; Disruption of ellipsoid zone (photoreceptor layer) |
| OCT Angiography (OCTA) | Non-invasive mapping of retinal vasculature; detects foveal avascular zone (FAZ) enlargement, capillary dropout | Right eye: FAZ enlarged - moderate foveal ischemia; areas of capillary non-perfusion |
| Intravenous Fluorescein Angiography (IVFA) | Map areas of capillary non-perfusion, leakage from microaneurysms; detect subclinical neovascularization | Right eye: Early frames - numerous hyperfluorescent dots (microaneurysms); Late frames - diffuse macular hyperfluorescence (leakage from CSME); Areas of capillary dropout; No neovascularization |
| Fundus Photography (Color + Red-Free) | Documentation and follow-up comparison; detects hemorrhages, exudates, microaneurysms | Documented Moderate NPDR with CSME (Right eye) |
| Gonioscopy | Rule out neovascularization of anterior chamber angle (NVA) | No NVA; open angles bilaterally |
| B-Scan Ocular Ultrasonography | Assess vitreous and posterior segment when media opacity (e.g., dense cataract) limits fundus view | Clear vitreous; retina attached; no tractional detachment |
| Visual Field Testing (Humphrey 24-2) | Detect scotomas from macular or nerve fiber damage | Central scotoma right eye; mild superior arcuate defect |
| Amsler Grid Test | Detect metamorphopsia (distortion) from macular edema | Wavy/distorted lines at central fixation (right eye) - positive |
| Color Fundus Imaging + Wide-Field Imaging | Detect peripheral retinal changes | No peripheral neovascularization; some mid-peripheral dot hemorrhages |
Source: Kanski's Clinical Ophthalmology 10th Edition (ISBN 9780443110993); The Wills Eye Manual (ISBN 9781975160753); Goldman-Cecil Medicine International Edition
VIII. MEDICATIONS PRESCRIBED
1. Glycemic Control (Systemic - Optimize for DR management)
| Drug | Dose | Route | Frequency | Note |
|---|---|---|---|---|
| Metformin | 1000 mg | Oral | Twice daily (with meals) | Continue; monitor renal function (eGFR 48) |
| Empagliflozin (SGLT2 inhibitor) | 10 mg | Oral | Once daily | Added for additional glycemic + renoprotective + cardioprotective benefit |
| Insulin (Glargine - Basal) | 20 units | Subcutaneous | Bedtime | Initiated given HbA1c 9.8% - inadequate oral control |
| Target HbA1c | <7.0% | - | - | Tight control reduces DR progression (DCCT/UKPDS) |
2. Blood Pressure Control
| Drug | Dose | Route | Frequency | Note |
|---|---|---|---|---|
| Ramipril (ACE Inhibitor) | 5 mg | Oral | Once daily | Renoprotective + BP control; first-line in diabetic nephropathy; target BP <140/80 mmHg |
| Amlodipine | 5 mg | Oral | Once daily | Continue |
| Target BP | <140/80 mmHg | - | - | Tight BP control especially beneficial for type 2 maculopathy |
3. Lipid Management
| Drug | Dose | Route | Frequency | Note |
|---|---|---|---|---|
| Atorvastatin | 40 mg (dose escalation from 20 mg) | Oral | Once daily | LDL target <100 mg/dL in DM; hyperlipidemia worsens DR |
| Fenofibrate | 145 mg | Oral | Once daily | Shown to slow DR progression; reduces hard exudates; beneficial for high TG |
4. Intravitreal Injections (PRIMARY EYE TREATMENT for CSME)
| Drug | Dose | Route | Frequency | Indication |
|---|---|---|---|---|
| Ranibizumab (Lucentis) OR Aflibercept (Eylea) | 0.5 mg / 2 mg respectively | Intravitreal injection (Right eye) | Monthly x 3-6 doses (loading), then as needed (PRN) or treat-and-extend | First-line FDA-approved anti-VEGF for center-involving DME |
| Bevacizumab (Avastin) | 1.25 mg | Intravitreal | Same schedule | Off-label but widely used; lower cost |
Anti-VEGF agents are first-line therapy for center-involving DME. - The Wills Eye Manual, p. 813
5. Intravitreal Corticosteroids (Second-line for DME - if poor anti-VEGF response)
| Drug | Dose | Route | Frequency | Note |
|---|---|---|---|---|
| Dexamethasone implant (Ozurdex) | 0.7 mg implant | Intravitreal | Every 4-6 months | FDA-approved; monitor for IOP rise and cataract |
| Fluocinolone acetonide implant (Iluvien) | 0.19 mg | Intravitreal | Long-acting (up to 3 years) | FDA-approved for chronic DME |
6. Laser Treatment (Adjunct / Selected cases)
| Procedure | Indication | Details |
|---|---|---|
| Focal Macular Laser Photocoagulation | Extrafoveal microaneurysms causing significant edema; adjunct to anti-VEGF | Targets specific leaking microaneurysms >500 µm from foveal center |
| Panretinal Photocoagulation (PRP) | NOT indicated currently (no PDR); reserved for high-risk PDR or NVI/NVA | If disease progresses to PDR |
7. Supplements & Supportive
| Drug | Dose | Purpose |
|---|---|---|
| Antioxidant vitamins (AREDS2 formula) | Daily | Macular protection |
| Lubricating eye drops | As needed | Dry eye (common in diabetics) |
| Aspirin 75 mg | Once daily | Cardiovascular risk reduction; does NOT increase risk of vitreous hemorrhage in DR |
| Iron supplements | As per requirement | Correct anemia (anemia worsens DR) |
IX. NURSING DIAGNOSIS & CARE PLAN
| Priority | Nursing Diagnosis | Goal | Interventions |
|---|---|---|---|
| 1 | Disturbed visual sensory perception related to macular edema and retinal changes | Prevent further vision loss; patient reports improved functional vision | Assess visual acuity daily; ensure timely intravitreal injections; educate about Amsler grid self-monitoring; reduce lighting glare |
| 2 | Ineffective health maintenance related to poorly controlled diabetes (HbA1c 9.8%) | HbA1c <7% within 3 months | Monitor blood glucose 4x/day; administer insulin as prescribed; reinforce dietary modifications; coordinate with diabetologist |
| 3 | Deficient knowledge regarding diabetes, retinopathy, and medication adherence | Patient verbalizes understanding of disease and treatment plan | Educate on link between blood sugar control and DR; explain intravitreal injection procedure; reinforce importance of regular eye exams |
| 4 | Risk for injury related to visual impairment | Patient remains free from falls and domestic injuries | Provide adequate lighting; advise on home safety; refer to low-vision rehabilitation if needed |
| 5 | Anxiety related to fear of blindness | Patient expresses reduced fear and coping ability | Reassure patient about treatment options; provide counseling; connect to diabetic support groups |
| 6 | Non-compliance with dietary plan and medications | Patient demonstrates consistent adherence | Simplified meal plan education; pillbox/calendar for medications; family involvement in diet planning |
| 7 | Fluid volume imbalance related to polyuria and nephropathy | Maintain adequate fluid balance | Monitor I/O; daily weight; restrict dietary protein and sodium given nephropathy |
X. PATIENT EDUCATION
- Blood glucose monitoring - at least twice daily; maintain a logbook
- Diet counseling - low-glycemic index diet, reduce simple sugars, high fiber
- Exercise - 30 minutes of moderate-intensity walking, 5 days/week (after medical clearance)
- Eye care - Annual dilated retinal examination even without symptoms; urgent visit if sudden vision loss, floaters, or flashes occur
- Amsler grid use - daily self-monitoring at home for detecting change in macular edema
- Foot care - daily foot inspection; avoid walking barefoot; regular podiatry review
- Avoid smoking - smoking accelerates vascular disease and DR progression
- BP and lipid control - strict adherence to medications; home BP monitoring
XI. FOLLOW-UP & PROGNOSIS
| Parameter | Schedule |
|---|---|
| Ophthalmology (Retina Clinic) | Every 4 weeks during anti-VEGF loading; then every 1-3 months |
| Diabetologist | Every 2-3 months until HbA1c <7% |
| Nephrologist | Every 3 months (CKD stage 3a) |
| Cardiologist | Every 6 months (LVH, diastolic dysfunction) |
| Repeat HbA1c | Every 3 months |
| Repeat OCT Macula | At each retina visit |
| Repeat IVFA | Every 6-12 months or when clinically indicated |
| Repeat Lipid Panel | Every 3-6 months |
Prognosis
- Risk of severe visual loss can be reduced to less than 5% with effective screening, glycemic control, and treatment based on ETDRS and anti-VEGF trials. - Kanski's Clinical Ophthalmology, 10th Edition, p. 521
- With current Moderate NPDR + CSME (right eye), the risk of progression to proliferative disease over 5 years is approximately 20-30% if glycemic control remains poor (HbA1c >9%)
- Aggressive HbA1c reduction to <7% significantly reduces the risk of DR progression (validated by the DCCT and UKPDS studies)
- The most common cause of visual impairment in this patient is diabetic macular edema, which is highly treatable with anti-VEGF agents
- Venous beading is noted in 1 quadrant (a significant predictor of progression to PDR) - requires vigilant follow-up
Key References:
- Kanski's Clinical Ophthalmology: A Systematic Approach, 10th Edition (ISBN 9780443110993), pp. 506-523
- The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease (ISBN 9781975160753), pp. 811-816
- Goldman-Cecil Medicine International Edition, 2-Volume Set (ISBN 9780323930345)
- Harrison's Principles of Internal Medicine 22E (2025, McGraw Hill Medical)
- Medscape - Diabetic Retinopathy Clinical Presentation
- PMC - Diabetic Retinopathy: Clinical Findings and Management
This is a shared conversation. Sign in to Orris to start your own chat.